Koshinski Asset Management Inc. Decreases Position in Boston Scientific Corporation $BSX

Koshinski Asset Management Inc. lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 29.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,256 shares of the medical equipment provider’s stock after selling 3,885 shares during the period. Koshinski Asset Management Inc.’s holdings in Boston Scientific were worth $994,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Swedbank AB grew its stake in shares of Boston Scientific by 114.5% during the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd grew its stake in shares of Boston Scientific by 33.5% during the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock worth $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $99.20 on Monday. The company’s fifty day moving average price is $101.29 and its 200 day moving average price is $101.77. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $146.99 billion, a P/E ratio of 59.05, a P/E/G ratio of 2.39 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business earned $0.62 EPS. Boston Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BSX. BTIG Research boosted their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Evercore ISI lowered their target price on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Truist Financial boosted their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.